1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Silk Road Medical Inc

Silk Road Medical, Inc.,is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company's flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke.
Erica Rogers

1213 Innsbruck Dr
Sunnyvale, California 94089-1317
Phone: 16505669060


Silk Road Medical Inc (NASDAQ: SILK): A Great Stock To Watch
Feb 24, 2024 12:30pm

Silk Road Medical Inc (NASDAQ:SILK) shares, rose in value, with the stock price down by -1.68% to the previous day’s close as strong demand from buyers drove the stock to $17.00. Actively observing the price movement in the last trading, the stock closed the session at $17.29. The value of beta (5-year monthly) was 1.45. […]

Source:Stocks Register
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Feb 07, 2024 21:30pm

SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28 th , 2024. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Bank of New York Mellon Corp Purchases 23,658 Shares of Silk Road Medical, Inc (NASDAQ:SILK)
Feb 05, 2024 09:20am

Bank of New York Mellon Corp boosted its position in Silk Road Medical, Inc (NASDAQ:SILK – Free Report) by 17.9% during the 3rd quarter, reports. The firm owned 155,799 shares of the company’s stock after purchasing an additional 23,658 shares during the quarter. Bank of New York Mellon Corp’s holdings in Silk Road Medical […]

Source:The AM Reporter
Heart Devices Focused Silk Road Medical Stock Gets an Upgrade - Analyst Says New CEO''s Initiatives Sets Stage For ''Back On Track''
Jan 19, 2024 18:35pm

Stifel upgraded Silk Road Medical Inc (NASDAQ: SILK ), noting the newly appointed CEO Chas McKhann’s first public speech at a major competitor healthcare conference, directly addressing/answering most of the concerns/uncertainties leading to Stifel’s downgrade in October . Stifel notes McKhann presented a compelling vision to revive the SILK story, addressing investor concerns early on. The absence of a CEO and uncertainties about the commercial team contributed to two quarterly misses and a sales guidance cut in 2023, causing a significant stock drop of approximately 77% from its 52-week high. The analyst has upgraded Silk Road Medical stock from Hold to Buy … Full story available on

Silk Road Medical spikes as Stifel upgrades on CEO remarks
Jan 19, 2024 16:59pm

Silk Road Medical (SILK) stock trades higher after Stifel raises recommendation to Buy and increases price target citing CEO''s compelling remarks. Read more here.

Source:Seeking Alpha
Accelerate Diagnostics, Silk Road Medical among healthcare movers
Jan 19, 2024 14:59pm

Gainers: Edgewise Therapeutics EWTX +28%. Silk Road Medical (SILK) +14%. Bullfrog AI Holdings (BFRG) +16%. Marpai (MRAI) +12%. ProMIS Neurosciences (PMN) +10%.

Source:Seeking Alpha
Texas Instruments To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday
Jan 19, 2024 12:36pm

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Raymond James raised ONEOK, Inc. (NYSE: OKE ) price target from $80 to $85. Raymond James analyst Justin Jenkins maintained an Outperform rating. ONEOK shares gained 3.2% to close at $71.25 on Thursday. See how other analysts view this stock. Stifel increased the price target for Silk Road Medical, Inc (NASDAQ: SILK ) from $9 to $20. Stifel analyst Rick Wise upgraded the stock from Hold to Buy. Silk Road Medical shares rose 1.5% to close at $13.18 on Thursday. See how other analysts view this stock. Goldman Sachs cut the price target for Chegg, Inc. (NYSE: CHGG ) from $10 to $8. Goldman Sachs analyst Eric Sheridan downgraded the stock from Neutral to Sell. Chegg shares … Full story available on